)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CNS Pharmaceuticals
CNS Pharmaceuticals (CNSP) investor relations material
CNS Pharmaceuticals Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary25 Aug, 2026
Executive summary
Annual meeting scheduled for September 30, 2026, at 12:00 PM EST, to be held virtually.
Shareholders are encouraged to review materials and vote on key proposals affecting governance and compensation.
Voting matters and shareholder proposals
Election of six directors for terms expiring at the 2027 annual meeting or until successors are elected.
Ratification of MaloncBailey, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory, non-binding vote on executive compensation.
Approval of amendments to the 2020 Stock Plan, including an increase of 650,000 authorized shares.
Authorization to adjourn the meeting if additional proxy solicitation is needed.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and amendments to the stock plan.
Director nominees include Faith Charles, Bettina Cockroft, Michal Fisher, Jeffry R. Keyes, Rami Levin, and Amy Mahery.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CNS Pharmaceuticals
- Shareholders will vote on director elections, auditor ratification, say-on-pay, and stock plan amendments.CNSP
Proxy filing - Strategic pivot targets high-value oncology and neurology assets with strong financial backing.CNSPInvestor presentation
- Net loss widened on higher expenses, but strong cash and new financing support strategic growth.CNSPQ2 2026
- Nearly 9.8 million shares registered for resale may cause significant dilution and price pressure.CNSPRegistration filing
- Strategic shift, $4.94M Q1 loss, and $22.5M May financing extend runway for acquisitions.CNSPQ1 2026
- Strategic pivot targets neurology and oncology with a new leadership team and asset-focused growth.CNSPInvestor presentation
- Strategic shift to neurology and oncology drives higher R&D costs and ongoing going concern risk.CNSPQ4 2025
- Pivotal brain cancer trial nears data, with new pipeline asset and strong financial footing.CNSPVirtual Investor CEO Connect
- TPI 287 was in-licensed, showing strong GBM efficacy and will enter pivotal trials in 2025.CNSPInvestor Update
Next CNS Pharmaceuticals earnings date
Q3 202613 Nov, 2026
CNS Pharmaceuticals
Next CNS Pharmaceuticals earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company engaged in the development of anti-cancer drug candidates. Its primary focus is on treatments for primary and metastatic cancers of the brain and central nervous system malignancies. The company's flagship drug candidate, Berubicin, is a novel anthracycline, notable for being the first of its kind to cross the blood-brain barrier. This drug is currently in development for the treatment of glioblastoma multiforme (GBM), a particularly aggressive and currently incurable form of brain cancer. In addition to Berubicin, CNS Pharmaceuticals is advancing WP1244, a drug technology that leverages anthracycline and distamycin-based scaffolds to create potent small molecule agents. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.